Sorrento Therapeutics Inc
Change company Symbol lookup
Select an option...
SRNE Sorrento Therapeutics Inc
KO Coca-Cola Co
VICI VICI Properties Inc
PLT Plantronics Inc
THG Hanover Insurance Group Inc
USB U.S. Bancorp
BAC Bank of America Corp
TCNNF Trulieve Cannabis Corp
RM Regional Management Corp
KTOS Kratos Defense and Security Solutions Inc

Health Care : Biotechnology | Small Cap Value
Company profile

Sorrento Therapeutics, Inc. is a clinical-stage and commercial biopharma company. The Company operates through two segments: Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next generation of cancer therapeutics. These modalities include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy (DAR-T), antibody-drug conjugates (ADC), as well as bispecific antibody approaches. Additionally, Sorrento Therapeutics segment also includes Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system to potentially achieve improved efficacy and fewer adverse effects than standard parenteral immunotherapy. The Scilex segment is organized around its non-opioid pain management operations.

Day's Change
-0.3563 (-4.89%)
B/A Size
Day's High
Day's Low

Today's volume of 6,705,844 shares is on pace to be much lighter than SRNE's 10-day average volume of 12,396,051 shares.




4 providers
August 18, 2020
Sorrento stock falls after company fires CFO

Sorrento Therapeutics Inc. (SRNE) shares fell in the extended session Tuesday after the biotech drug maker said it fired its chief financial officer. In a Securities and Exchange Commission filing, Sorrento said CFO Jiong Shao's employment was...(MarketWatch)

August 05, 2020
UPDATE: 'Clueless' investors just keep driving this 'stupidly bullish' stock market higher, CNBC's Jim Cramer says

By Shawn Langlois, MarketWatch Is this the 'dumbest action' of the year? That's CNBC "Mad Money" host Jim Cramer shaking his head at 'clueless' investors...(MarketWatch)

May 27, 2020
UPDATE: Sorrento Therapeutics stock is a buy on the 50% chance of a COVID-19 antidote, analyst says

By Tomi Kilgore, MarketWatch Share price target of implies a near five-fold gain on expected successful development of antibody cocktail Shares of Sorrento Therapeutics Inc. rallied Tuesday, after a Wall Street analyst suggested the...(MarketWatch)

May 26, 2020
Sorrento Therapeutics started at buy with $24 stock price target at Dawson James Securities

(END) Dow Jones Newswires May 26, 2020 07:30 ET (11:30 GMT) Copyright (c) 2020 Dow Jones & Company, Inc.(MarketWatch)

May 18, 2020
Sorrento stock's intraday high of $10 was nearly 4 times Thursday's closing price

(END) Dow Jones Newswires May 18, 2020 14:39 ET (18:39 GMT) Copyright (c) 2020 Dow Jones & Company, Inc.(MarketWatch)

Sorrento Therapeutics' stock gains 1.9%, but pares earlier surge of as much as 48%

(END) Dow Jones Newswires May 18, 2020 14:38 ET (18:38 GMT) Copyright (c) 2020 Dow Jones & Company, Inc.(MarketWatch)

Here's what it will take for the stock market to hit a new record within 2 months

By Nigam Arora Moderna's announcement on progress toward a coronavirus vaccine could start the second leg of a short squeeze Many investors not familiar with the mechanics of short squeezes are confused by the strength of the stock market...(MarketWatch)

Sorrento Therapeutics' stock soars 44% premarket, after rocketing 158% on Friday

(END) Dow Jones Newswires May 18, 2020 07:30 ET (11:30 GMT) Copyright (c) 2020 Dow Jones & Company, Inc.(MarketWatch)

May 15, 2020
Sorrento Therapeutics' stock soars on massive volume after upbeat report on COVID-19 antibody experiment

Shares of Sorrento Therapeutics Inc. (SRNE) blasted 153% higher on very heavy volume in afternoon trading Friday, putting it on track to close at a near 2-year high, after the biopharmaceutical company provided an upbeat assessment of the results...(MarketWatch)

May 08, 2020
Sorrento's stock jumps on antibody plans with Mount Sinai Health System

Shares of Sorrento Therapeutics Inc. (SRNE) gained 8.9% in trading on Friday after the company said it plans to develop an antibody cocktail treatment for patients at risk or with new infections of COVID-19 in partnership with Mount Sinai Health...(MarketWatch)

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.